IL91302A - Pharmaceutical compositions comprising nalmefene or naltrexone for treating arthritic and associated inflammatory diseases - Google Patents

Pharmaceutical compositions comprising nalmefene or naltrexone for treating arthritic and associated inflammatory diseases

Info

Publication number
IL91302A
IL91302A IL9130289A IL9130289A IL91302A IL 91302 A IL91302 A IL 91302A IL 9130289 A IL9130289 A IL 9130289A IL 9130289 A IL9130289 A IL 9130289A IL 91302 A IL91302 A IL 91302A
Authority
IL
Israel
Prior art keywords
nalmefene
naltrexone
patient
pharmaceutical compositions
administered
Prior art date
Application number
IL9130289A
Other languages
English (en)
Other versions
IL91302A0 (en
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of IL91302A0 publication Critical patent/IL91302A0/xx
Publication of IL91302A publication Critical patent/IL91302A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL9130289A 1989-01-04 1989-08-14 Pharmaceutical compositions comprising nalmefene or naltrexone for treating arthritic and associated inflammatory diseases IL91302A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/293,196 US4863928A (en) 1989-01-04 1989-01-04 Method of treatment for arthritic and inflammatory diseases

Publications (2)

Publication Number Publication Date
IL91302A0 IL91302A0 (en) 1990-03-19
IL91302A true IL91302A (en) 1994-05-30

Family

ID=23128099

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9130289A IL91302A (en) 1989-01-04 1989-08-14 Pharmaceutical compositions comprising nalmefene or naltrexone for treating arthritic and associated inflammatory diseases

Country Status (9)

Country Link
US (1) US4863928A (no)
EP (1) EP0377272A3 (no)
JP (1) JPH02184628A (no)
AU (1) AU619937B2 (no)
CA (1) CA1333772C (no)
DK (1) DK674389A (no)
IL (1) IL91302A (no)
NO (1) NO894296L (no)
ZA (1) ZA898013B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013739A (en) * 1986-10-07 1991-05-07 Bernard Bihari Method of treating chronic fatigue syndrome using an opiate receptor antagonist
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5376662A (en) * 1993-12-08 1994-12-27 Ockert; David M. Method of attenuating nerve injury induced pain
SE9304236D0 (sv) * 1993-12-22 1993-12-22 Astra Ab New use
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
WO2001040269A2 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US7879211B2 (en) * 2001-07-13 2011-02-01 Arkray, Inc. Analyzing instrument, lancet-integrated attachment for concentration measuring device provided with analyzing instrument, and body fluid sampling tool
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
MXPA04011327A (es) * 2002-05-17 2005-08-15 Jenken Biosciences Inc Opioides y compuestos similares a opioides y usos de los mismos.
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1615646B2 (en) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
CA2522471A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
US8088787B2 (en) * 2004-05-12 2012-01-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CN104248763A (zh) 2005-03-07 2014-12-31 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CA2609985A1 (en) * 2005-06-03 2007-05-10 The University Of Chicago Modulation of cell barrier dysfunction
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
JP2009534384A (ja) * 2006-04-19 2009-09-24 ジル・ピー・スミス オピオイドアンタゴニストによる炎症性および潰瘍性腸疾患の治療
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
JP5358587B2 (ja) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド （ｒ），（ｒ）−２，２’−ビス−メチルナルトレキソンの製造及び用途
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases

Also Published As

Publication number Publication date
EP0377272A3 (en) 1991-09-25
AU4763090A (en) 1990-08-30
IL91302A0 (en) 1990-03-19
ZA898013B (en) 1990-08-29
NO894296D0 (no) 1989-10-27
DK674389D0 (da) 1989-12-29
CA1333772C (en) 1995-01-03
US4863928A (en) 1989-09-05
DK674389A (da) 1990-07-05
AU619937B2 (en) 1992-02-06
EP0377272A2 (en) 1990-07-11
NO894296L (no) 1990-07-05
JPH02184628A (ja) 1990-07-19

Similar Documents

Publication Publication Date Title
CA1333772C (en) Method of treatment for arthritic and inflammatory diseases
CA1333569C (en) Method of treatment for autoimmune diseases
US5502058A (en) Method for the treatment of pain
US4994466A (en) Method of treatment for multiple sclerosis
EP0229022A2 (en) Novel pharmaceutical compositions comprising analgesic agents or caffeine
JP2000508341A (ja) 片頭痛の治療法及び薬効の強化組成物
CA2411564A1 (en) Method of treating pain using nalbuphine and opioid antagonists
Batenhorst et al. Pharmacologic evaluation of loratadine (SCH 29851), chlorpheniramine and placebo
Hägermark Influence of antihistamines, sedatives, and aspirin on experimental itch
GB2271059A (en) Pharmaceutical compositions comprising aconitane derivatives
ZA200403162B (en) Method and composition for potentiating an opiate analgesic.
US4877791A (en) Method of treatment for interestitial cystitis
KR100969634B1 (ko) 글루코사민 또는 글루코사민 유도체를 포함하는 아토피성피부염 치료용 조성물 및 이를 사용하여 아토피성 피부염을치료하는 방법
JP2702400B2 (ja) 糖尿病性腎症治療用スロデキサイド含有医薬
SE466481B (sv) Analgetiska och anti-inflammatoriska kompositioner innefattande koffein
EP0514023B1 (en) Use of glycine/NMDA receptor ligands for the manufacture of a medicament for the treatment of drug dependence and withdrawal
AU701014B2 (en) Treatment of disease and conditions associated with macrophage infiltration in particular stroke and myocardial infarction
Moyer et al. Laboratory and clinical observations on mecamylamine as a hypotensive agent.
Yang et al. Progress in the treatment of Osteoarthritis with avocado–soybean unsaponifiable
JPH045231A (ja) 慢性痛用鎮痛剤
Waisman et al. Naloxone is protective against indomethacin-induced intestinal ulceration in the rat
Hersh et al. Narcotic receptor blockade and its effect on the analgesic response to placebo and ibuprofen after oral surgery
Chakravarti et al. Zuclopenthixol acetate (5% in ‘Viscoleo’): single-dose treatment for acutely disturbed psychotic patients
JPH07507289A (ja) 抗炎症剤
EP0232697B1 (en) Pharmaceutical compositions containing acth fragments for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies

Legal Events

Date Code Title Description
HE Change of address of proprietor(s)
KB Patent renewed
RH1 Patent not in force